Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
CORTES, JORGE E
One or more keywords matched the following items that are connected to CORTES, JORGE E
Item TypeName
Academic Article Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Academic Article Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Academic Article Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Academic Article Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Academic Article Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Academic Article Congestive heart failure is a rare event in patients receiving imatinib therapy.
Academic Article Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Academic Article Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Concept Neoadjuvant Therapy
Concept Drug Therapy, Combination
Concept Combined Modality Therapy
Concept Therapies, Investigational
Concept Salvage Therapy
Concept Treatment Outcome
Concept Therapeutic Equivalency
Concept Withholding Treatment
Concept Treatment Refusal
Concept Treatment Failure
Concept Antiretroviral Therapy, Highly Active
Academic Article Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Academic Article AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Academic Article Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
Academic Article Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?
Academic Article Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
Academic Article Differences in CD33 intensity between various myeloid neoplasms.
Academic Article Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.
Academic Article Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Academic Article Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Academic Article Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Academic Article Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Academic Article Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Academic Article Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Academic Article Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Academic Article Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Academic Article Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Academic Article Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
Academic Article A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Academic Article A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Academic Article Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Academic Article Rituximab in relapsed or refractory hairy cell leukemia.
Academic Article Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Academic Article The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.
Academic Article Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Academic Article Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Academic Article Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Academic Article Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
Academic Article Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Academic Article Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Academic Article New targeted approaches in chronic myeloid leukemia.
Academic Article Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Academic Article Chronic myeloid leukemia: diagnosis and treatment.
Academic Article Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Academic Article Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Academic Article Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Academic Article Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Academic Article PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Academic Article Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Academic Article Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Academic Article Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Academic Article Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
Academic Article Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Academic Article Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Academic Article Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Academic Article Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
Academic Article Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Academic Article Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Academic Article Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Academic Article Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Academic Article Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Academic Article Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Academic Article Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Academic Article Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
Academic Article Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Academic Article Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Academic Article Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Academic Article Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia.
Academic Article Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Academic Article Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Academic Article Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Academic Article Experimental therapeutics for patients with myeloproliferative neoplasias.
Academic Article Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
Academic Article Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Academic Article Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
Academic Article Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Academic Article Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Academic Article Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Academic Article Dasatinib for the treatment of chronic myeloid leukemia.
Academic Article A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Academic Article Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Academic Article Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Academic Article Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
Academic Article Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Academic Article Evolution of therapies for chronic myelogenous leukemia.
Academic Article Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Academic Article Treatment options for chronic myeloid leukemia.
Academic Article Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Academic Article A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Academic Article A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Academic Article Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Academic Article Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
Academic Article Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).
Academic Article Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.
Academic Article Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data.
Academic Article SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
Academic Article Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
Academic Article Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.
Academic Article Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
Academic Article Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Academic Article Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Academic Article Antiangiogenic therapy in leukemia.
Academic Article Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Academic Article A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Academic Article Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Academic Article Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors.
Academic Article Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Academic Article Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Academic Article Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Academic Article New agents in the treatment of acute lymphocytic leukaemia.
Academic Article Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Academic Article SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Academic Article Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Academic Article Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Academic Article Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Academic Article Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Academic Article Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Academic Article Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Academic Article Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Academic Article Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
Academic Article Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Academic Article High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Academic Article Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
Academic Article A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Academic Article Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Academic Article Natural history and staging of chronic myelogenous leukemia.
Academic Article Accelerated and blastic phases of chronic myelogenous leukemia.
Academic Article Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Academic Article Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Academic Article Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Academic Article Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Academic Article Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Academic Article Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Academic Article International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Academic Article Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Academic Article Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Academic Article Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Novel approaches in the treatment of systemic mastocytosis.
Academic Article Advances in the therapy of chronic idiopathic myelofibrosis.
Academic Article Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Academic Article Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Academic Article The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Academic Article Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Academic Article A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Academic Article The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Academic Article Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Academic Article Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Academic Article Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Academic Article BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Academic Article Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Academic Article Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Academic Article Management of patients with resistant or refractory chronic myelogenous leukemia.
Academic Article Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Academic Article The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Academic Article Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Academic Article Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Academic Article Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Academic Article Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Academic Article Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
Academic Article Treatment selection after imatinib resistance in chronic myeloid leukemia.
Academic Article Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Academic Article Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Academic Article Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Academic Article Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
Academic Article Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Academic Article Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
Academic Article Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Academic Article Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Academic Article Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Academic Article Tyrosine kinase inhibitors: the first decade.
Academic Article Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Academic Article Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Academic Article Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Academic Article A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article Monitoring molecular response in chronic myeloid leukemia.
Academic Article Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Academic Article Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Academic Article FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Academic Article Mutant BCR-ABL clones in chronic myeloid leukemia.
Academic Article Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Academic Article Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Academic Article Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Academic Article Chronic myeloid leukemia: mechanisms of resistance and treatment.
Academic Article Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Academic Article Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Academic Article Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Academic Article Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Academic Article EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Academic Article Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Academic Article Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
Academic Article Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Academic Article Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
Academic Article Bosutinib in the treatment of chronic myelogenous leukemia.
Academic Article Is acute myeloid leukemia a liquid tumor?
Academic Article Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
Academic Article Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Academic Article Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
Academic Article Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.
Academic Article Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
Academic Article Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
Academic Article The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
Academic Article Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Academic Article Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Academic Article Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Academic Article The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Academic Article Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Academic Article GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
Academic Article Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Academic Article Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.
Academic Article Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Academic Article Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Academic Article Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Academic Article Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Academic Article Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Academic Article High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Academic Article Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Academic Article CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Academic Article Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Academic Article Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Academic Article Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Academic Article Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Academic Article Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
Academic Article Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Academic Article Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Academic Article Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Academic Article Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Academic Article Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Academic Article Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Academic Article Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Academic Article Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Academic Article Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Academic Article Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Academic Article Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Academic Article Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Academic Article Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Academic Article Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Academic Article Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
Academic Article Investigational strategies in chronic myelogenous leukemia.
Academic Article Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Academic Article Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Academic Article Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Academic Article Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Academic Article The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Academic Article Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Academic Article Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Academic Article Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Academic Article Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Academic Article Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Academic Article Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Academic Article MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Academic Article In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Academic Article Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Academic Article Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Academic Article Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Academic Article Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Academic Article Important therapeutic targets in chronic myelogenous leukemia.
Academic Article Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
Academic Article Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Academic Article Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Academic Article PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Academic Article Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Academic Article Biphenotypic acute leukaemia: a case series.
Academic Article Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Academic Article Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
Academic Article The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Academic Article Nilotinib therapy in chronic myelogenous leukemia.
Academic Article Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Academic Article Targeted therapy in chronic myeloid leukemia.
Academic Article Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Academic Article Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Academic Article A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Academic Article Imatinib therapy for chronic myeloid leukemia: where do we go now?
Academic Article Therapeutic options for patients with clonal and idiopathic hypereosinophia.
Academic Article Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Academic Article Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
Academic Article Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.
Academic Article Potential role of sorafenib in the treatment of acute myeloid leukemia.
Academic Article Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Academic Article Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Academic Article Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Academic Article Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Academic Article Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Academic Article Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
Academic Article Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Academic Article Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Academic Article Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Academic Article A multinational study of health state preference values associated with chronic myelogenous leukemia.
Academic Article Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Academic Article High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Academic Article Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Academic Article Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Academic Article The next generation of therapies for chronic myeloid leukemia.
Academic Article Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.
Academic Article Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Academic Article First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Academic Article Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Academic Article Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Academic Article Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
Academic Article Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
Academic Article Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.
Academic Article Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Academic Article Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Academic Article Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Academic Article Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Academic Article Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Academic Article New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Academic Article Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Academic Article Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Academic Article Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Academic Article Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
Academic Article Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Academic Article The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Academic Article Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Academic Article Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Academic Article Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Academic Article Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Academic Article Molecular targeted therapy in acute myeloid leukemia.
Academic Article Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
Academic Article How I treat newly diagnosed chronic phase CML.
Academic Article Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Academic Article Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.
Academic Article Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Academic Article Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Academic Article Re-emergence of interferon-a in the treatment of chronic myeloid leukemia.
Academic Article Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.
Academic Article Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Academic Article Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
Academic Article Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Academic Article Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
Academic Article Measuring the symptom burden associated with the treatment of chronic myeloid leukemia.
Academic Article Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Academic Article Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Academic Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Academic Article Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
Academic Article Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Academic Article Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
Academic Article Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Academic Article Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Academic Article Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Academic Article Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.
Academic Article A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Academic Article Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
Academic Article Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Academic Article Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
Academic Article Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Academic Article BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Academic Article Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Academic Article Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Academic Article Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Academic Article Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Academic Article Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Academic Article The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Academic Article Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Academic Article Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Academic Article Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Academic Article Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Academic Article Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Academic Article The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Academic Article New agents in acute myeloid leukemia and other myeloid disorders.
Academic Article Novel therapies for patients with chronic myeloid leukemia.
Academic Article Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
Academic Article A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Academic Article Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Academic Article Discontinuation of imatinib therapy after achieving a molecular response.
Academic Article Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Academic Article Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Academic Article 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Academic Article Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Academic Article Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Academic Article Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Academic Article A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Academic Article Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Academic Article Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Academic Article The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Academic Article Current and emerging treatment options in chronic myeloid leukemia.
Academic Article Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Academic Article Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
Academic Article Homoharringtonine for the treatment of chronic myelogenous leukemia.
Academic Article On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Academic Article The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Academic Article Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Academic Article Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Academic Article Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Academic Article Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Academic Article First-line therapy for chronic myeloid leukemia: Past, present, and future.
Academic Article Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Academic Article Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Academic Article Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Academic Article Azacitidine for the treatment of myelodysplastic syndrome.
Academic Article Optimizing first-line therapy for patients with chronic myeloid leukemia.
Academic Article Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
Academic Article Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.
Academic Article New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
Academic Article Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Academic Article Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
Academic Article Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Academic Article Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Academic Article Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Academic Article Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Academic Article Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Academic Article Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Academic Article Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.
Academic Article Molecular resistance: an early indicator for treatment change?
Academic Article Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Academic Article Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Academic Article The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Academic Article Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.
Academic Article Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Academic Article Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
Academic Article Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.
Academic Article Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Academic Article Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications.
Academic Article Central nervous system involvement in adult acute lymphocytic leukemia.
Academic Article Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Academic Article Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Academic Article Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Academic Article Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Academic Article Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Academic Article Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Academic Article Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Academic Article A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Academic Article t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Academic Article Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Academic Article Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Academic Article New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Academic Article Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Academic Article Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Academic Article Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Academic Article Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Academic Article Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Academic Article Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Academic Article Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Academic Article Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Academic Article Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
Academic Article Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.
Academic Article Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Academic Article Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Academic Article Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Academic Article Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Academic Article Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
Academic Article Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.
Academic Article Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Academic Article Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Academic Article Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
Academic Article Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Academic Article Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Academic Article Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Academic Article Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.
Academic Article Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
Academic Article Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Academic Article Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Academic Article Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Academic Article A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
Academic Article Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
Academic Article Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.
Academic Article Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Academic Article Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Academic Article Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience.
Academic Article Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
Academic Article Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Academic Article Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
Academic Article A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Academic Article Progress in acute myeloid leukemia.
Academic Article Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
Academic Article New treatment for acute myelogenous leukemia.
Academic Article Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Academic Article Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine.
Academic Article Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Academic Article A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Academic Article Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
Academic Article Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.
Academic Article Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
Academic Article Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Academic Article Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
Academic Article Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Academic Article Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Academic Article Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Academic Article Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Academic Article Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Academic Article Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.
Academic Article Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Academic Article Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Academic Article Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Academic Article Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
Academic Article Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Academic Article Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Academic Article Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Academic Article Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Academic Article Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors
Academic Article Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
Academic Article Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML
Academic Article Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Academic Article Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors
Academic Article The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies
Academic Article First-line treatment for patients with CML in chronic phase
Academic Article Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia
Academic Article Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
Academic Article Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies
Academic Article Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure
Academic Article Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia
Academic Article Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis
Academic Article Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Academic Article Characterization of UCN-01 specific binding to human α1-acidic-glycoprotein
Academic Article Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Academic Article Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Academic Article Personalized medicine and targeted therapy of leukemia
Academic Article Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Academic Article BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response
Academic Article Management of imatinib-resistant patients with chronic myeloid leukemia
Academic Article Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
Academic Article Nilotinib for the treatment of chronic myeloid leukemia after imatinib failure
Academic Article Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
Academic Article A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Academic Article Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure
Academic Article Development and targeted use of nilotinib in chronic myeloid leukemia
Academic Article A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
Academic Article Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase
Academic Article Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival
Academic Article Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Academic Article Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Academic Article Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
Academic Article Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Academic Article Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Academic Article Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Academic Article Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
Academic Article Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na?ve Chronic Myeloid Leukemia Patients Trial.
Academic Article A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
Academic Article Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Academic Article Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Academic Article Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Academic Article Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
Academic Article Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Academic Article Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Academic Article Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
Academic Article Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Academic Article KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Academic Article Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Academic Article Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
Academic Article Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Academic Article Mutations in AML: prognostic and therapeutic implications.
Academic Article Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Academic Article A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Academic Article A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Academic Article Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Academic Article Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Academic Article Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Academic Article Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Academic Article Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
Academic Article Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Academic Article A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
Academic Article A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Academic Article Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
Academic Article Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Academic Article First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Academic Article Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Academic Article Therapy-related myelofibrosis does not appear to exist.
Academic Article Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.
Academic Article Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
Academic Article Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Academic Article Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
Academic Article Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Academic Article Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Academic Article Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Academic Article A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Academic Article Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Academic Article Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
Academic Article Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Academic Article Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Academic Article Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
Academic Article Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Academic Article Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Academic Article Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
Academic Article A second-generation TKI should always be used as initial therapy for CML.
Academic Article Tyrosine Kinase Inhibitor-associated Fibrothorax.
Academic Article Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Academic Article Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Academic Article Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
Concept Molecular Targeted Therapy
Academic Article Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Academic Article Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Academic Article Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Academic Article Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Academic Article Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Academic Article Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Academic Article Treatment-free remission in chronic myeloid leukemia.
Academic Article Long-term results of frontline dasatinib in chronic myeloid leukemia.
Academic Article Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Academic Article Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Academic Article A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
Academic Article Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
Academic Article Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.
Academic Article Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
Academic Article Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Academic Article Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Academic Article A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Academic Article Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Academic Article An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Academic Article Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
Academic Article Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Academic Article BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Academic Article Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.
Academic Article Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Academic Article Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Academic Article Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Academic Article Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Academic Article A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Academic Article CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Academic Article Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.
Academic Article A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Academic Article Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.
Academic Article Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Academic Article A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
Academic Article Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Academic Article Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia.
Academic Article Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
Search Criteria
  • Therapeutics